- Sparsentan. Dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist, Treatment of focal segmental glomerulosclerosis, Treatment of IgA nephropathy2020 | First Faculty of Medicine
- Should renin-angiotensin system inhibitors be discontinued in patients with covid-19 infection?2022 | First Faculty of Medicine
- AT(1) receptor blocker, but not an ACE inhibitor, prevents kidneys from hypoperfusion during congestive heart failure in normotensive and hypertensive rats2021 | First Faculty of Medicine, Second Faculty of Medicine
- Management of arterial hypertension in patients with chronic heart failure2013 | First Faculty of Medicine
- Irbesartan in the treatment of patients with diabetes mellitus and renal dysfunction Irbesartan in the treatment of patients with diabetes mellitus and renal dysfunction2016 | Third Faculty of Medicine
- Possible prooxidant effect of angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor (AT1) antagonists in neural tissue2013 | Faculty of Medicine in Pilsen
- Despite Similar Reduction of Blood Pressure and Renal ANG II and ET-1 Levels Aliskiren but not Losartan Normalizes Albuminuria in Hypertensive Ren-2 Rats2010 | Second Faculty of Medicine